Xenios AG has become part of Fresenius Medical Care. A press release reports that Xenios is driving innovation in minimally invasive lung and heart assist, and is first to offer a complete product range that runs on a common platform. It adds that Fresenius Medical Care is a global market leader in dialysis, an extracorporeal medical procedure offering multiple analogies to lung support technologies.
According to the press release, in the field of dialysis, Fresenius Medical Care successfully forged the path from innovation to a globally leading company—offering “an outstanding prerequisite to be also successful in the field of extracorporeal lung support”.
Jürgen Böhm, chief executive officer of Xenios AG, says: “Xeniois AG will continue to manufacture and market their lung and heart assist product portfolio. Our strategy remains in place, and the processes and contacts remain unchanged. Xenios AG will continue to serve their customers with the clinical support team and information on Xenios Campus to advance minimally invasive lung and heart assist therapies.”
The closing of the transaction is now subject to approval by the cartel authorities.
